Latest Capital Funding News

Investigator Silver has locked in a robust Definitive Feasibility Study for its Paris Silver Project, backed by a strategic A$55 million placement to fast-track early works and financing.

GreenTech Metals has consolidated a dominant West Pilbara position by acquiring 70% of the Munni Munni PGE-Cu-Ni Project and completed a cost-saving Phase 1 drilling and historic core resampling program. Early data hints at significant resource expansion ahead of a JORC 2012 upgrade.

Resolution Minerals has raised A$20 million in a strongly supported institutional placement to accelerate exploration and development at its US Horse Heaven Project, while preparing for a NASDAQ listing to boost its US market presence.

European Resources Limited (ASX: ERE) has repriced and relaunched a renounceable rights issue to raise up to $3.4 million, partially underwritten by Mahe Capital for $1.5 million, to fund metallurgical and exploration work at its Korsnäs rare earth project in Finland and Slovakian tenements.

Bailador Technology Investments is backing DASH Technology Group with an additional $5 million investment at a valuation below its current carrying value, reflecting cautious optimism amid market pressures.

Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

GreenTech Metals has appointed James Rattenbury as CEO to spearhead development of its Munni Munni platinum group metals project, signalling a strategic push in the West Pilbara mining hub.

Macquarie Group has reported a solid third quarter for FY26, with significant profit gains in asset management and capital divisions, alongside steady growth in banking services. The group maintains a strong capital buffer, positioning itself well despite a cautious economic outlook.

Shares of Apiam Animal Health Limited (ASX – AHX) have been suspended from trading following court approval of its acquisition by entities controlled by Adamantem Capital Fund II. This marks a significant ownership change for the animal health company.

Apiam Animal Health’s acquisition scheme by Adamantem Capital has been legally approved, leading to the suspension of its shares on the ASX. Key dates for dividend payments and scheme implementation are now set.

The Supreme Court of New South Wales has approved the scheme of arrangement for Adamantem Capital Fund II’s acquisition of Apiam Animal Health, marking a pivotal step toward the deal’s completion and the suspension of Apiam shares on the ASX.